Sign in

CIK 0001840229 · <br>Emerging growth company

MiNK Therapeutics, Inc.

Sign in to watch
Ticker
INKT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
212-994-8250
Business address
149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
Former names
AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
  1. ARS Other Annual Report to Security Holders
  2. DEF 14A Proxy Proxy Statement
  3. PRE 14A Proxy Proxy Statement (Preliminary)
  4. 10-K Report Annual Report
  5. 8-K Event Results of operations
  6. 4 Grant or award Director acquired 1,536 shares (grant or award)
  7. 4 Grant or award Director acquired 1,849 shares (grant or award)
  8. 4 Grant or award Director acquired 1,593 shares (grant or award)
  9. 4 Grant or award Director acquired 2,019 shares (grant or award)
  10. 4 Grant or award Director acquired 2,033 shares (grant or award)
  11. 8-K Event Bylaws or fiscal year change · Shareholder vote results
  12. DEF 14A Proxy Proxy Statement
  13. 4 Grant or award Director acquired 12,286 shares (grant or award)
  14. 3 Insider Initial Statement of Ownership
  15. PRE 14A Proxy Proxy Statement (Preliminary)
  16. 4 Grant or award Director acquired 24,229 shares (grant or award)
  17. 4 Grant or award Director acquired 24,400 shares (grant or award)
  18. 4 Grant or award Director acquired 20,987 shares (grant or award)
  19. 4 Grant or award Director acquired 20,476 shares (grant or award)
  20. 10-Q Report Quarterly Report

Page 5 of 14 · 267 filings